DALLAS and NEW YORK, Dec. 10, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of$2.55 per share for aggregate gross proceeds of $6.0 million. Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date. The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.
“In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs,” stated Jeffrey B. Davis, President & CEO. He continued, “This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward.”
Read more »
Company Gains Traction With Top Healthcare Insurance Companies Less Than Two Months Into Full-Scale Lead Product Launch
Dallas, TX and New York, NY, December 9, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks. Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harvard Pilgrim and Medicaid.
Read more »
Significant Step Validates Company’s Unique Value-Driven Strategy For Exploiting Multi-applicable Oral Drug Delivery Technology Platform
Dallas, TX and New York, NY, December 08, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major global pharmaceutical company to test Access’ oral insulin formulation based upon its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology. Access will provide CobOral insulin to the pharmaceutical company. Access anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month.
Read more »
MuGard Website Features Video And Additional Written Clinician Feedback
Dallas, TX and New York, NY, December 3, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.
The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link: www.MuGard.com/testimonials/.
Read more »
Digg!
Del.icio.us
NIH estimates that 90% of all radiation patients and 40% of chemotherapy patients experience oral mucositis! #MuGard #cancer